<DOC>
	<DOCNO>NCT00437463</DOCNO>
	<brief_summary>To evaluate efficacy ACE inhibitor ramipril treatment early IgA nephropathy .</brief_summary>
	<brief_title>Treatment Immunoglobulin A ( IgA ) Nephropathy Angiotensin-Converting Enzyme ( ACE ) Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin A</mesh_term>
	<criteria>biopsyconfirmed IgA nephropathy proteinuria le 0.5 g per day , normal blood pressure , serum creatinine 120 Âµmol/l pregnant nursing mother , woman childbearing potential without effective method birth control history myocardial infarction , congestive heart failure , medical indication necessitate use ACE inhibitor evidence clinically significant hepatic , gastrointestinal , autoimmune disease history malignancy , drug alcohol abuse participation previous trial ACE inhibitor take investigational drug within past 30 day know history sensitivity / allergy ACE inhibitor The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>